Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.
Diabetes Metab. 44, 235-242 (2017)
Background/Objectives. - As only 1% of clinically eligible subjects choose to undergo surgical treatment for obesity, other options should be investigated. This study aimed to assess the effects of intensive lifestyle modification (ILM) with or without 3-mg liraglutide daily vs. sleeve gastrectomy (SG) on BMI after 1 year.Subjects/methods. - In this study performed at an Italian university hospital, non-diabetic patients eligible for bariatric surgery were recruited from a weight-loss clinic and had the option to choose from three possible weight-loss programmes up to an allocation of 25 subjects in each arm matched by Bil and age. ILM consisted in 813 kcal of a very low-calorie diet (VLCD) for 1 month, followed by a diet of 12 kcal/kg body weight of high protein and high fat for 11 months plus 30 min of brisk walking daily and at least 3 h of aerobic exercise weekly. SG patients followed a VLCD for 1 month and a free diet thereafter. Patients were evaluated at baseline and at 1, 3, 6, 9 and 12 months.Results. - A total of 75 patients were enrolled; retention was 100% in the SG and 85% in the two medical arms. SG reduced BMI by 32% (P < 0.001 vs. medical arm), while ILM + liraglutide and ILM led to BMI reductions of 24% and 14%, respectively (P < 0.001). More women allocated themselves to the ILM + liraglutide group. Weight loss was 43 kg with SG, 26 kg with ILM + liraglutide and 15 kg with ILM alone. Lean body mass reductions were -11.6 kg with SG, -6.3 kg with ILM and -8.3 kg with ILM + liraglutide. Prevalence of prediabetes was significantly lower with ILM + liraglutide, and insulin resistance was reduced by about 70% by both ILM + liraglutide and SG vs. 39% by ILM alone. Cardiometabolic risk factors were greatly reduced in all three groups.Discussion. - At least in the short-term, liraglutide 3.0 mg once daily associated with drastic calorie- intake restriction and intensive physical activity promoted a 24% weight loss, which was almost two times greater than ILM alone and only about 25% less than with SG, while preserving lean body mass. Although this study was non-randomised, it was designed to explore the efficacy of medical treatments for obesity in everyday clinical practice.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
4.101
1.393
15
10
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Body Composition ; Bariatric Surgery ; Lifestyle Modification ; Liraglutide ; Obesity ; Very Low-calorie Diet; Low-calorie Diet; Bariatric Surgery; Medical Therapy; Weight Management; Randomized-trial; Obese-patients; Adults; Overweight; Outcomes; Placebo
Sprache
englisch
Veröffentlichungsjahr
2017
HGF-Berichtsjahr
2017
ISSN (print) / ISBN
1262-3636
e-ISSN
1878-1780
Zeitschrift
Diabetes & metabolism
Quellenangaben
Band: 44,
Heft: 3,
Seiten: 235-242
Verlag
Elsevier
Verlagsort
Issy-les-Moulineaux
Institut(e)
Institute of Pancreatic Islet Research (IPI)
POF Topic(s)
90000 - German Center for Diabetes Research
Forschungsfeld(er)
Helmholtz Diabetes Center
PSP-Element(e)
G-502600-012
G-502600-007
G-502600-007
WOS ID
WOS:000437808500006
PubMed ID
29398254
Erfassungsdatum
2018-02-07